All In Biotech

Drug Trial Radar · NCT00658970

Evaluation of KX2-391 in Patients With Advanced Malignancies

A Combined Rising Single-dose (RSD) and Rising Multiple-dose (RMD)Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies

Last checked: Nov 20, 2026Latest source record: Jun 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 2007

Primary completion

Mar 2010

Study completion May 2011

Sponsor

Lead sponsor
Athenex, Inc.Industry
Sponsor type
Industry
First posted
Apr 16, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.

Conditions

  • Solid Tumors
  • Lymphoma

Interventions

  • KX2-391Drug

    2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine maximum tolerated dose of the drugTime frame: 64 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.